Get the Stockscreener App
0.0007
0.00%
0.00
Paxmedica Inc stock is traded at $0.0007, with a volume of 189.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$0.0007
Open:
$0.0007
24h Volume:
189
Relative Volume:
14.19
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-13.49M
P/E Ratio:
-0.000392
EPS:
-1.7861
Net Cash Flow:
$-7.62M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
-93.93%
1Y Performance:
-85.81%
1-Day Range:
$0.0007
$0.0007
1-Week Range:
$0.0007
$0.0007
52-Week Range:
$0.0007
$0.0007
Paxmedica Inc Stock (PXMD) Company Profile
Compare PXMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PXMD
Paxmedica Inc
|
0.0007 | 0 | 0 | -13.49M | -7.62M | -1.7861 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Paxmedica Inc Stock (PXMD) Latest News
Strategic Execution in Focus for Paxmedica Investors - AD HOC NEWS
ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast - Defense World
Comparing PaxMedica (NASDAQ:PXMD) & ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Paxmedica’s PAX-101 Under the Microscope: Pipeline Progress and FDA Milestones - AD HOC NEWS
MorphoSys (NASDAQ:MOR) vs. PaxMedica (NASDAQ:PXMD) Head to Head Comparison - Defense World
Autism Spectrum Disorder Market to Reach USD 4.07 Billion - GlobeNewswire
PXMD Stock Institutional Owners - Quiver Quantitative
Plus Therapeutics Regains Compliance With Two Nasdaq Listing Rules - marketscreener.com
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Major Nasdaq Purge: 14 Companies Face Permanent Delisting After Trading Suspensions - Stock Titan
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica announces board resignations amid transition - Investing.com
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Groundbreaking China Patent for Autism Treatment Breakthrough After 100 Years - Stock Titan
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - Yahoo Finance
Autism Spectrum Disorder Therapeutics Market size is set to grow by USD 766.1 million from 2024-2028, Increasing prevalence of asd to boost the market growth, Technavio - PR Newswire
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
Tardimed Sciences Llc Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - GlobeNewswire
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA - marketscreener.com
PaxMedica Receives Emergency Request for IV Suramin from - GlobeNewswire
Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies By Benzinga - Investing.com UK
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission - Yahoo Finance
PaxMedica, Inc. (PXMD) stock price, news, quote and history - Yahoo Finance UK
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation - Nasdaq
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
PaxMedica prices stock and warrant offering at $1.30 per unit By Investing.com - Investing.com Canada
PaxMedica, Inc. (PXMD) latest stock news and headlines - Yahoo Finance UK
Why Is PaxMedica (PXMD) Stock Down 40% Today? - TradingView — Track All Markets
PaxMedica progresses with PAX-101 for sleeping sickness By Investing.com - Investing.com UK
PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast - GlobeNewswire
PaxMedica Surges After Publication Of Statistically Significant Data From Its Autism Spectrum Study - Nasdaq
Gapping stocks in Tuesday's session - ChartMill
PaxMedica Announces 1-for-17 Reverse Stock Split - Yahoo Finance
PaxMedica (NASDAQ: PXMD) Reports on Low-Dose Suramin for ASD Research - Digital Journal
Curious about the stocks that are showing activity before the opening bell on Thursday? - ChartMill
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD) - GlobeNewswire
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - Yahoo Finance
PaxMedica Comments on Common Stock Volatility - GlobeNewswire
PaxMedica CEO Interviewed by The BRAIN Foundation - GlobeNewswire
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder - GlobeNewswire
PaxMedica and PoloMar to investigate emodin in ASD trial - Clinical Trials Arena
PaxMedica Enters Research Collaboration Agreement With - GlobeNewswire
Paxmedica Inc Stock (PXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Cap:
|
Volume (24h):